In recent years, adelmidrol’s oral administration has demonstrated efficacy in the management of experimental colitis induced by DNBS in mice via inhibiting the translocation of Nuclear Factor kappa-B (NF-κB) and promoting a reduction in Intercellular Adhesion Molecule 1 (ICAM1) expression through its specific interaction with PPAR-γ receptors [7]. Here, NFKB1 is linked to colitis.